Table 1 Characteristics of studies
From: Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis
Study | Country | N | Years of diagnosis | Follow-up, yr | Stage | Age, yr | Timing of BMI measurement | BMI category | Adjustment variables |
|---|---|---|---|---|---|---|---|---|---|
Min Zhang et al. | China | 207 | 1999-2000 | Minimum, 3 | all stages | 1. at diagnosis | BMI < 20.0 | Age, stage, grade, ascites, residual lesions, chemotherapy, total energy intake, menopausal status | |
Mean alive, 46.7 | 2. 5 year ago | 20.0 ≤ BMI ≤ 22.4 | |||||||
Mean dead, 51.6 | 3. at age 21 y | 22.5 ≤ BMI ≤ 24.9 | |||||||
25.0 ≤ BMI | |||||||||
Joanne Kotsopoulos et al. | Canada | 1423 | 1995-2004 | mean 7.4 | all stages | under, 50.75 | 5 years prior to diagnosis | BMI < 18.5 | Age at diagnosis, BRCA mutation status, stage and histologic subtype |
range, 0.59-15.72 | |||||||||
normal, 56.23 | 18.5 ≤ BMI ≤ 25 | ||||||||
overweight, 57.84 | 25 ≤ BMI ≤ 30 | ||||||||
obese, 57.78 | 30 ≤ BMI | ||||||||
Yang Zhou et al. | USA | 388 | 1998-2003 | all: 9.28 ± 8.68 | all stages | Median, 58.6 | 1. during 20s | BMI < 25 | Age, stage, histology, education, oral contraceptive use, menopausal status and HRT use, parity, age at first birth, family history of ovarian cancer, time from ovarian cancer diagnosis to study enrollment |
BMI ≥ 25 | |||||||||
BMI < 25: 8.67 ± 7.96 | 2. 5 years before diagnosis | BMI < 25 | |||||||
BMI ≥ 25 | |||||||||
BMI ≥ 25: 9.95 ± 9.38 | 3. 9 months post-chemotherapy | ||||||||
Ling Yang et al. | National wide (UK, Sweden, Italy, Norway, Finland) | 635 | 1993-1995 | Range, 50-74 | all stages | 50-74 | 1. Age 18 | BMI < 18.5 | Age at diagnosis, FIGO stage and WHO grade of differentiation |
18.5 ≤ BMI ≤ 25 | |||||||||
2. 1 year prior to ovarian cancer diagnosis | 25 ≤ BMI ≤ 30 | ||||||||
30 ≤ BMI | |||||||||
I. SKI’RNISDO’ TTIR et al. | Sweden | 635 | 1975-2004 | Mean, 6.8 | I,II | Mean 60.1 | at the start of the adjuvant therapy | BMI < 18.5 | Stage, grade, histology |
18.5 ≤ BMI ≤ 25 | |||||||||
25 ≤ BMI ≤ 30 | |||||||||
30 ≤ BMI | |||||||||
Range, 1.6-17.8 | |||||||||
Anette Kjærbye-Thygesen et al. | Denmark | 295 | 1994-1999 | Median, 7.3 | III | Range, 35-79 | 1. BMI age at 20-29y | BMI < 18.5 | Age, radicality of surgery, histology, platinum-based chemotherapy, smoking status, continuous BMI 5 years before diagnosis |
18.5 ≤ BMI ≤ 24.9 | |||||||||
Range, 5.4-9.5 | 2. BMI 5years before diagnosis | 25.0 ≤ BMI | |||||||
Crystal P. Tyler, | USA | 425 | 1980-1982 | Median, 9.7 | all stages | 20-54 | 1. adult BMI(within 6 months of diagnosis) | lowest quartile (<20.7) the second (20.8–22.5) third (22.6–24.9) fourth (≥25.0) quartiles | Age at diagnosis, stage at diagnosis, histologic type, oral contraceptive use, parity, menopausal status, presence of any other chronic conditions including diabetes, high blood pressure, chronic kidney disease, gallbladder disease, myocardial infarction, heart disease, high cholesterol, paralysis, or stroke |
2. BMI at age 18, | |||||||||
3. weight change from age 18 to adult | |||||||||
Kirsten B. Moysich et al. | USA | 395 | 1982-1998 | NA (≥9) | all stages | mean(SD) | self-reported | BMI < 18.5 | age at diagnosis, FIGO stage |
alive: 47.5(14.1) | 1. current height and weight | 18.5 ≤ BMI ≤ 25 | |||||||
dead: 58.3(12.3) | 2. weight before dx | 25 ≤ BMI ≤ 30 | |||||||
30 < BMI | |||||||||
INGIRIDUR SKÍRNISDÓTTIR & BENGT SORBE | Sweden | 446 | 1994-2003 | Mean, 3.9 | all stages | Mean, 62.5 | at the start of the | BMI ≤25 | Age, stage, histology |
Range, 0-12.3 | range, 25-91 | adjuvant therapy | BMI > 25 | ||||||
James C. Pavelka et al. | USA | 149 | 1996-2003 | Not stated | III-IV | Range, 18-79 | first postoperative visit | BMI < 18.5 | nil |
18.5 ≤ BMI ≤ 25 | |||||||||
25 ≤ BMI ≤ 30 | |||||||||
30 < BMI | |||||||||
Schlumbrecht, M. | USA | 127 | 2002-2007 | mean, 3.1 (0.3-7.2) | not stated | not stated | not stated | BMI < 18.5 | not stated |
18.5 ≤ BMI ≤ 25 | |||||||||
25 ≤ BMI ≤ 30 | |||||||||
30 < BMI | |||||||||
Dolecek, T.A. et al. | USA | 341 | 1994-1998 | Not stated | I-IV | Range, 18-74 | Self-reported BMI at diagnosis | BMI < 18.5 | Age, race, stage, grade, residual lesions, smoking status, oral contraceptive use, parity |
18.5 ≤ BMI ≤ 25 | |||||||||
25 ≤ BMI ≤ 30 | |||||||||
30 ≤ BMI | |||||||||
Fotopoulou, C. et al. | Germany | 306 | 2000-2010 | 11.7 months (0.1-62.9) | I-IV | 58(18–92) | Not stated | BMI < 25 | Residual tumor, grade, positive lymph node status, age, FIGO stage, Ascites, IMO level 2/3 involvement, nonserous histology, distant metastasis |
BMI ≥ 25 | |||||||||
Lamkin, D.M. et al. | USA | 74 | 2001-2005 | Not stated | I-IV | 62(33–87) | Not stated | BMI as continuous variable | None (univariate analysis) |
Nagle, C.M. et al. | Australia | 609 | 1990-1993 | Median 7.3 yrs (5–8.3) | I-IV | 18-79 | Prior to illness | BMI <22.2 | FIGO stage, age, grade, total energy intake (Kilocalories), BMI, residual, ascites, smoking status, parity and length of OCP use |
22.2-25.8 | |||||||||
BMI > 25.8 | |||||||||
Schlumbrecht, M.P. et al. | USA | 194 | 1977-2009 | Median f/u 60.9 months (1–383) | I-IV | 44.9(14–79) | 8 wks after primary surgical intervention | BMI <25 | Stage, Taxane, Current alcohol use, year of diagnosis, current smoker, age at diagnosis, hormone tx after adjuvant ctx |
25 ≤ BMI < 30 | |||||||||
30 ≤ BMI < 35 | |||||||||
35 ≤ BMI | |||||||||
Schildkraut, J.M. et al. | USA | 197 | 1980-1982 | Not stated | I-IV | 20-54 | At diagnosis | BMI > 27.9 | None (univariate analysis) |